+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Competitor Analysis: Kallikrein Inhibitors 2017

  • ID: 4228593
  • Report
  • April 2017
  • Region: Global, Global
  • 17 Pages
  • La Merie Publishing
1 of 2

The present Competitive Intelligence report about Kallikrein Inhibitors and bradykinin receptor antagonists provides a competitor evaluation in the field of marketed drugs and novel approaches for prophylaxis and treatment of hereditary angioedema (HAE) and new investigational compounds for treatment of diabetic macular edema (DME) as of April 2017.

Inhibitors of kallikrein and antagonists of the bradykinin receptors are based on small molecules, antibodies, proteins, peptides as well as RNA. Based on the commercial success of marketed drugs for prophylaxis of HAE, next generation molecules were designed to improve convenience of mode of administration and frequency of administration. In addition, the use of kallikrein inhibitors for ophthalmic indications is being evaluated with the most advanced compounds in clinical studies.

The report includes a compilation of currently active projects in research and development of small molecule, antibody, protein, peptide and oligonucleotide inhibitors ofkallikrein. In addition, the report lists company-specific R&D pipelines of plasma and tissue kallikrein inhibitors.

Competitor projects are listed in a tabular format providing information on:

  • Drug Codes
  • Target/Mechanism of Action
  • Class of Compound
  • Company
  • Product Category
  • Indication
  • R&D Stage
  • Additional comments with a hyperlink leading to the source of information.

About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

Note: Product cover images may vary from those shown
2 of 2

1. Kallikrein Inhibitors 2017
Plasma Kallikrein Inhibitors for Hereditary Angioedema
Plasma Kallikrein Inhibitors for Diabetic Macular Edema
Tissue Kallikrein Inhibitors

2. Corporate Kallikrein Inhibitor R&D Pipelines

Note: Product cover images may vary from those shown
3 of 2